News & Updates

Holding or decreasing the dose of outpatient beta blocker therapy does not seem to affect the incidence of tachyarrhythmias in patients with heart failure with reduced ejection fraction (HFrEF) admitted for acute decompensated heart failure (ADHF), reports a study.

The oral fatty acid synthase (FASN) inhibitor denifanstat appears to produce meaningful improvements in metabolic dysfunction-associated steatohepatitis (MASH) and stage 2–3 fibrosis, as shown in the results of a phase IIb trial.

Treatment with survodutide, which has previously shown its efficacy in reducing body weight and glycaemia in people with obesity or type 2 diabetes, is well tolerated by patients with compensated or decompensated cirrhosis, reports a study.

Patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) who use opioids end up with higher healthcare utilization and costs compared with those who do not use opioids, reports a study.

Treatment with semaglutide can significantly lower the risk of time to first heart failure (HF) events or cardiovascular (CV) death in type 2 diabetes (T2D) patients with chronic kidney disease (CKD), a recent study has shown.

Use of statins helps prevent deaths in patients hospitalized with COVID-19, as shown by the results of a systematic review and meta-analysis.